Lupisoz-D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, leading to prolonged acid suppression and promoting mucosal healing. The sustained-release (SR) formulation of Lupisoz-D ensures gradual and consistent drug release, enhancing therapeutic efficacy and patient compliance. This combination is particularly beneficial in patients with acid-related disorders accompanied by delayed gastric emptying. Lupisoz-D Capsule SR should be administered as directed by a healthcare professional, typically before meals. Caution is advised in patients with known hypersensitivity to either component, hepatic impairment, or underlying cardiac conditions. Potential side effects may include headache, dry mouth, abdominal cramps, or extrapyramidal symptoms. Regular monitoring and adherence to prescribed dosage are essential to optimize treatment outcomes and minimize adverse effects.